Author/Authors :
Rehman, Hibba Tul University of Vermont Medical Center - Hematology and Medical Oncology - Burlington - VT , USA , Jehangir, Waqas University of Vermont Medical Center - Hematology and Medical Oncology - Burlington - VT , USA , Karabachev, Alexander University of Vermont College of Medicine - Larner College of Medicin - Burlington - VT , USA , Tsao, Jackie University of Vermont College of Medicine - Larner College of Medicin - Burlington - VT , USA , Anker, Christopher J. University of Vermont Medical Center - Radiation Oncology- Burlington - VT , USA , Garapati, Sree Susmitha University of Vermont Medical Center - Endocrinology Diabetes & Metabolism- Burlington - VT , USA , Kikut, Janusz K. University of Vermont Medical Center - Radiology- Burlington - VT , USA
Abstract :
Paragangliomas are rare neuroendocrine tumors that arise from chromaffin-containing tissue. Surgical resection and/or radiationare used for locoregional disease, and reduction of tumor burden with systemic therapy is reserved for metastatic disease.Iobenguane I-131, somatostatin analog (octreotide), and Sunitinib are noncytotoxic options for treatment, whilecyclophosphamide, vincristine, and dacarbazine (CVD) and temozolomide are often used as initial chemotherapy options asstudies have shown that they offer some tumor response. However, there are no randomized clinical trials demonstratingprolonged survival with the use of chemotherapeutics in metastatic cases. Investigation of alternative therapies that providesurvival benefit is thus necessary. We present a case of a 69-year-old female with metastatic malignant paragangliomapresenting as a left parapharyngeal neck mass, which metastasized after surgery, requiring radiation therapy for bony metastasiswho was treated with a radioisotope somatostatin analog for disease progression
Keywords :
Metastatic Malignant Paraganglioma Presenting , Neck Mass Treated , Radiolabeled Somatostatin Analog , CVD
